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INTRODUCTION
Since the first case descriptions in December 2019, the COVID-19 pandemic has prompted the
development of diagnostic technologies at an unprecedented pace, and the pattern of collaborative
scientific data sharing during this period has followed a similar path. A recent bibliometric study
demonstrated that the research publication response to the COVID-19 pandemic was much more
effective than in other recent epidemic events, namely the 2015–16 Zika virus epidemic and the
2014–16 Ebola virus outbreak in West Africa (1). Concerning only preprint publications, there
were over 2,500 articles related to COVID-19 in the first 4 months of the pandemic, as opposed
to only 88 articles in total related to both the Zika and Ebola viruses in the same epidemiological
periods. Additionally, by the end of April, the total number of COVID-19 publications, including
preprints and peer-reviewed articles, had already surpassed 16,000 (1). When we searched PubMed
specifically for scientific publications related to COVID-19 diagnostics (search terms: COVID-19
AND Diagnostics), it returned at least 930 specific papers in the first 5 months of the COVID-
19 epidemic period (limited to December 2019–April 2020), while a similar search for Zika virus
retrieved only nine publications related to diagnostics in the same time period (limited to March
2015–July 2015). Other recent publications have also discussed the efficiency of open data sharing
during the early part of the COVID-19 pandemic, particularly of epidemiological and diagnostic
data, and how it contributed to early interventions (2, 3).
The speed by which viral genomic sequences weremade publicly available during the COVID-19
pandemic also demonstrates the fast pace of data sharing during the period. As early as December
31, 2019, 19 genomic sequences of the SARS-CoV-2 virus were already available through the
GISAID database (gisaid.org), which now has over 40,000 viral genome sequences shared by
laboratories around the globe. As a comparison, during the Ebola virus outbreak, it took nearly
3 years for the number of sequenced viral genomes to reach 1,500 sequences (4). The early
availability of SARS-CoV-2 genomic sequences contributed to the rapid development of the gold
standard molecular diagnostic assays for COVID-19, based on reverse-transcription polymerase
chain reaction (RT-qPCR), made available by the World Health Organization (WHO) and the US
Centers for Disease Control and Prevention (CDC), still in early 2020 (5–7). Additionally, it also
contributed to the development of streamlined protocols for complete viral genome sequencing
and analysis (8, 9) and of lab-based serology assays that use recombinantly-produced SARS-CoV-2
proteins (10) (Figure 1A).
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RAPID DATA SHARING CONTRIBUTED TO
DEVELOPMENT AND VALIDATION OF
COVID-19 DIAGNOSTICS
A good example demonstrating how rapid data sharing
contributed to the development of diagnostics during the
COVID-19 pandemic is shown by the first RT-qPCR assay design
developed by researchers from the Charité – Universitätsmedizin
Berlin Institute of Virology in Germany (12). The first SARS-
CoV-2 viral genome sequence was made publicly available for
immediate public health support as soon as 10 days after official
reporting of the early cases of atypical pneumonia in China to the
WHO. Only 3 days later (on January 13, 2020), the first RT-qPCR
assay was made available to the international community. A few
days later, positive controls were already available through the
European Virus Archive (EVAg) repository (13). Soon after, on
February 4, 2020, the US Food and Drug Administration (FDA)
issued an emergency use authorization (EUA) to the CDC’s 2019
Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic
Panel. It did not take long for new studies describing SARS-CoV-
2 viral load kinetics in different samples to be published for the
different genomic targets (N, E, and RdRP), and this contributed
to improvements in diagnostic protocols early in the epidemic.
Compared to Zika virus epidemic, it was only nearly 1 year after
first case descriptions in Brazil that the US FDA issued an EUA
for the Trioplex assay on March 17, 2016.
The widespread adoption of preprint servers (such as
medrxiv.org and biorxiv.org) for sharing research data
before peer review has also allowed rapid publication of
studies evaluating the performances of different diagnostic
technologies and has contributed to a clearer understanding
of emerging technologies that will potentially aid in the
diagnosis and surveillance of COVID-19 in the near future
(Figure 1A). Different studies have demonstrated that preprint
publications were underutilized during the Zika and Ebola
virus epidemics, despite being important tools for accelerating
scientific development during disease outbreaks (1, 14). Now,
COVID-19 related preprint publications have permitted
foreseeing emerging roles for technologies based on loop-
mediated isothermal amplification (LAMP) and CRISPR-based
diagnostics, as these technologies are indeed appearing now in
peer-reviewed publications and starting to reach commercial
applications. In an interesting recent development, for example,
isothermal amplification by reverse-transcription (RT)-LAMP
was combined with specific CRISPR/Cas12 detection of SARS-




Now, we can easily follow the development of new COVID-
19 diagnostic technology into commercial products due to
data sharing initiatives, such as the Foundation for Innovative
New Diagnostics (FIND; finddx.org/covid-19/) and 360 Dx
coronavirus test tracker (360dx.com). From data made available
on over 590 COVID-19 diagnostic tests (as of April 24,
2020), we can have a clear view of the point-of-care (PoC)
diagnostic technology landscape (Figure 1B). Although the
numbers of commercially manufactured COVID-19 molecular
tests and immunoassays are similar, there is clearly a higher
proportion of decentralized tests that are based on immunoassays
when compared to molecular methods (Figure 1B). This is
probably due to the technological maturity of colloidal-
gold immunochromatographic assays. Conversely, the greater
number of lab-based commercial molecular tests for COVID-
19 is due to the high number of companies offering RT-qPCR
based kits (Figure 1B). Regarding regulatory status, there is a
high proportion of CE-marked PoC tests that comply with the
relevant European Union regulations (Directive 98/79/EC on
in vitro diagnostics), although this does not necessarily mean
that these tests are commercially available in Europe (Figure 1C).
Additionally, novel EUAs for COVID-19 tests are being granted
in a continuous basis by regulatory agencies worldwide, including
the US FDA (fda.gov) and the Brazilian ANVISA (http://portal.
anvisa.gov.br/coronavirus).
As of late April 2020, the WHO still did not recommend the
use of PoC rapid immunodiagnostic tests (RDTs) for patient care
and public health decision-making in the COVID-19 context
(16, 17). However, most of the commercially available tests to
date are in fact based on lateral flow immunoassay (LFIA)
technologies for detecting SARS-CoV-2 antigens or human
IgM/IgG antibodies (Figure 1D). Regarding PoC or near-PoC
commercially manufactured molecular tests, two technological
strategies are clear: (i) methods that provide simplified
workflows for nucleic acid amplification tests (NAATs); and
(ii) methods based on isothermal amplification by LAMP.
In the former category, tried-and-tested diagnostic platforms
with simplified sample-to-results workflows have already been
introduced by major companies, such as the Xpert Xpress
SARS-CoV-2 test (Cepheid) and the ID Now COVID-19 assay
(Abbott Diagnostics).
CONCLUSION
The rapid development of diagnostic technology is an essential
component of an epidemic preparedness strategic plan (18).
Accordingly, the technological landscape of the development of
COVID-19 diagnostics is rapidly evolving, with new information
being generated on a daily basis. Different platforms for
open and fast data sharing have been contributing to this
rapid diagnostic development, that include: fast availability of
genomic data in public sequence repositories (e.g., gisaid.org);
open collaboration in preliminary data analysis using science
community blogs and discussion forums (e.g., virological.org);
publication of periodic reports by universities and international
organizations (e.g., the WHO); real-time sharing of diagnostic
validation results (e.g., finddx.org); and particularly the use
of preprint servers for early publication of research studies
(e.g., medRxiv and bioRxiv). Recent studies have shown that
these fast publication platforms are driving much of the
debate about the COVID-19 pandemic, despite the intrinsic
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FIGURE 1 | The COVID-19 diagnostic technology landscape. (A) A (non-exhaustive) list of the current and emerging technologies for laboratory-based or
decentralized (near or at the point-of-care) COVID-19 diagnosis. Methods for clinical diagnosis of COVID-19, such as chest computed tomography, are discussed
elsewhere (6, 7, 11). *Disambiguation: despite being frequently used in the COVID-19 context, the abbreviation RT-PCR is more appropriate to the traditional method
of reverse-transcription PCR. For real-time (quantitative) reverse-transcription PCR, such as in SARS-CoV-2 detection, it is more appropriate to use RT-qPCR or
rtRT-PCR. FDA EUA, US Food and Drug Administration Emergency Use Authorization (EUA); PoC, point-of-care; NAT, nucleic acid test. (B) Categories of commercially
manufactured COVID-19 diagnostic tests, as of late Apr 2020. (C) Regulatory status of the available tests. EUA, Emergency Use Authorization; CE-IVD, Conformité
Européenne (EU certification)-in vitro diagnostics; RUO, research use only. (D) Major technologies used in current point-of-care diagnostic tests for COVID-19.
limitations associated with the unregulated sharing of research
results at such fast pace (19). Therefore, to ensure the
integrity and quality of rapidly shared studies, the research
community is already putting into practice several control
mechanisms, at various levels (20–22). From researcher-led
initiatives, that include the creation of open peer-review
platforms for improving the quality of COVID-19-related
preprints (21), to publisher-led initiatives, such as the fast
peer-review of research studies previously posted to non-peer
reviewed platforms, these mechanisms will altogether contribute
to guarantee the credibility of speedy information delivery during
the pandemic (19–22).
This opinion paper was not meant to present exhaustive
information on COVID-19 diagnosis, but rather to make an
overview of currently available technologies in the academic
and commercial settings for laboratory and PoC testing. For
excellent reviews on strategies for COVID-19 diagnosis, we refer
the readers to Cheng et al. (6), Tang et al. (7), and Udugama et al.
(11). Besides, up-to-date information on COVID-19 diagnostic
technology can be found at the following sources:
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• WHO Coronavirus disease (COVID-19) technical guidance:
Laboratory testing for 2019-nCoV in humans (23)
• FIND: COVID-19 Diagnostics Resource Center (24)
• U.S. FDA Coronavirus Disease 2019 (COVID-19) (25).
As new COVID-19 diagnostic technologies are introduced,
studies aimed at validating their usefulness in clinical settings will
be of crucial importance (26). In this sense, collaborative data
sharing on SARS-CoV-2 diagnostic performance evaluation, such
as the initiatives led by FIND (24) and the WHO, will contribute
to rapid adoption of new diagnostic technology and will inform
public health decisions on a global scale.
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